Hold the Chemo

TAILORx trial researchers say that most women with early stage breast cancer who receive a low recurrence risk score on Genomic Health's Oncotype DX test do well on hormonal therapy alone and are disease-free after five years, as GenomeWeb has reported.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.